Skip to content

Effects of microbiological rapid on-site evaluation (M-ROSE)-guided use of antibiotics on prognosis of lung infections

Effects of microbiological rapid on-site evaluation (M-ROSE)-guided use of antibiotics on prognosis of lung infections

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064577
Enrollment
Unknown
Registered
2022-10-12
Start date
2022-10-10
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung infection, ARDS

Interventions

Group 1 :
Group 2:

Sponsors

Lianyungang First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patient has signed the informed consent; 2. The age of the patient is >=18 years old; 3. The gender of the patient is not limited to men and women; 4. Inpatients who meet the diagnostic criteria of HAP or CAP, within 1 week of onset; 5. Qualified BALF or sputum or bronchoscopic puncture (or biopsy) specimens can be obtained.

Exclusion criteria

Exclusion criteria: 1. The medical history of the transferred patients shows that the pathogenic bacteria infection has been confirmed; 2. The patients died without starting any treatment plan since the starting date of observation; 3. Other reasons that the researchers think are not suitable to participate in this study, such as the patient's antibiotic allergy during the early treatment process, the antibacterial treatment plan must be replaced, resulting in the inability to obtain real and effective experimental data.

Design outcomes

Primary

MeasureTime frame
Clinical outcomes;

Secondary

MeasureTime frame
Hospital stay;Fever relief time;

Countries

China

Contacts

Public ContactShi Jiaxin

Lianyungang First People's Hospital

shijiaxin909@126.com+86 18961325783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026